Athebio AG’s Post

🥳 #Athebio has a new Chief Executive Officer! 🥳 We are excited to welcome Thomas Huber, PhD as new CEO to Athebio AG 😊😊😊 (https://lnkd.in/eAdqZ432). With his more than 15 years of experience in drug development in different roles at Novartis, Almirall, biotech incubator Ridgeline Discovery and Granite Bio Thomas is the perfect addition to our team!   His scientific expertise integrates biotherapeutic technologies, immunology, and pharma/biotech principles, facilitating advanced therapeutic approaches. This will significantly contribute to our customer-centric partnering model, anchored on our Athebody® DARPin platform. Moreover, his hands-on experience with therapeutic #antibodies, #multispecifics, therapeutic proteins, #AAV, and #DARPins provides him with a deep understanding of the realm of protein binders. Athebio’s co-founder and #DARPin mastermind Patrik Forrer, who has served as CEO since the company's inception, will transition to the role of Acting Chief Scientific Officer (CSO), in addition to his position as Chairman of the Board.   Thomas, welcome to #Athebio! Here's to a journey of #innovation and #collaboration ahead! #biotechnology  #athebody  #drugdiscovery #proteinengineering